Predictive biomarkers for MS

Stanford UniversityandPfizer Inc.researchers have reported that levels of IL-7 could help predictwhich multiple sclerosis patients will not respond to interferon-b therapy.¹ Serum analysis of IL-7 together with a second marker identified last year by the Stanford team, IL-17F, which was only able to identify about 10% of nonresponders on its own, could predict up to one-third of nonresponders.

Stanford has spun out Atreca Inc. to develop predictive blood tests based on the findings...